Skip to content
drillr.ai

CTNM

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ · USHealthcareBiotechnology
$13.53-4.92%

Price as of Jul 20, 2026

CTNM news

Contineum Therapeutics, Inc. Class A Common Stock news

A server-rendered, paginated timeline of the latest available company news.

  1. Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

    Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry - Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) - Blocking LPAR1 inhibits key steps in the fibrosis pathway with potential targets in several therapeutic indications Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biop

    Business Wire ·

  2. Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on March 12, 2026 (Grant Date), the Compensation Committee of the Company’s Board of Directors granted an inducement award consisting of a non-qualified stock o

    Business Wire ·

  3. Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

    Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) - Topline data from the exploratory PIPE-791 Phase 1b trial in patients with chronic pain is expected in the second quarter of 2026 Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharma

    Business Wire ·